New cancer drug LM-2417 enters human trials for advanced tumors
NCT ID NCT06682780
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tests a new drug called LM-2417, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. About 320 adults aged 18-80 with good performance status are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
FuDan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.